Hausa
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

AI Helps Write
AI Helps Write
Rukunan Magani
Magungunan da aka Fi So
Maganin Cutar Kanjamau: Ci gaba da Maganin Ciwon Daji

Maganin Cutar Kanjamau: Ci gaba da Maganin Ciwon Daji
CAR-T don Glioblastoma

CAR-T don Glioblastoma
Allurar Sodium ta Nusinersen: Fata ga Ƙarfin ...

Allurar Sodium ta Nusinersen: Fata ga Ƙarfin ...
Maganin CAR-T don Ciwon Ciki

Maganin CAR-T don Ciwon Ciki
Maganin CAR-T don Ciwon Neuroblastoma Mai Lalacewa/Mai Rage Radadi

Maganin CAR-T don Ciwon Neuroblastoma Mai Lalacewa/Mai Rage Radadi
CAR-T don Lupus Erythematosus na Tsari (SLE)

CAR-T don Lupus Erythematosus na Tsari (SLE)
Cutar Sickle Cell da Thalassemia

Cutar Sickle Cell da Thalassemia
Sabuwar Maganin Halitta Yana Ba da Sabon Fata ga Marasa Lafiyar Sickle Cell da Thalassemia

Sabuwar Maganin Halitta Yana Ba da Sabon Fata ga Marasa Lafiyar Sickle Cell da Thalassemia
FUCASO: Maganin Juyin Juya Hali na BCMA CAR-T Mai Cikakken Juyin Juya Hali tare da Inganci da Tsaro Mara Daidaitawa

FUCASO: Maganin Juyin Juya Hali na BCMA CAR-T Mai Cikakken Juyin Juya Hali tare da Inganci da Tsaro Mara Daidaitawa
Yin Amfani da Kwayoyin NK: Ci Gaba da Maganin Ciwon daji Fiye da Iyakoki

Yin Amfani da Kwayoyin NK: Ci Gaba da Maganin Ciwon daji Fiye da Iyakoki
0102030405
Cikakken Bayani Kan Maganin Cutar Leukemia Mai Muhimmanci

Cikakken Bayani Kan Maganin Cutar Leukemia Mai Muhimmanci

Maganin CAR-T, wanda aka yi wa lakabi da Chimeric Antigen Receptor T-Cell Immunotherapy, wata hanya ce ta zamani ta maganin kwayoyin halitta wadda ta ƙunshi gyara ƙwayoyin T na majiyyaci don kai hari da kuma lalata ƙwayoyin cutar kansa. Ba kamar magungunan gargajiya ba, maganin CAR-T an tsara shi ne ga kowane majiyyaci kuma yana buƙatar tattara ƙwayoyin T daga jinin majiyyaci kafin a sake haɗa su cikin jiki bayan injiniyan kwayoyin halitta.

    Tuntube mu

    Alamomin CAR-T

    ● Cutar sankarar lymphoblastic mai tsanani ta B-cell

    ●Myeloma da yawa

    ●Cutar sankarar lymphocytic na yau da kullun

    ●Lymphoma na NonHodgkin

    ●Yaɗuwar babban lymphoma na B-cell

    ●SLE (Tsarin Lupus Erythematosus)

    ●Myasthenia gravis

    ●Wasu cututtukan da ke shafar garkuwar jiki

    Kyakkyawan aikin asibiti na CAR-T

    Alamomi ga CD19+20CAR-T: Marasa lafiya da cutar lymphoma ba ta Hodgkin ba ta B-cell

    Kudin CR na wata ɗaya

    Kudin PR na wata ɗaya

    Kudin wata ɗaya KO

    CRS≥3

    CRES≥3

    71.95%(59/82)

    25.6（21/82）

    97.55(80/82)

    12.19%(10/82)

    0

    Alamomi ga CD19+22CAR-T: Maganin cutar sankarar jini ta B-lymphocytic da ta sake dawowa da kuma wadda ba ta da tabbas a cikin CD19

    Kudin CR na wata ɗaya

    Kudin PR na wata ɗaya

    Kudin wata ɗaya KO

    CRS≥3

    CRES≥3

    92.1%(35/38)

    Kashi 7.9%(3/38)

    100%(38/38)

    Kashi 15.79%(6/38)

    0

    Alamomi ga BCMACAR-T: Maganin sake dawowa da kuma rashin ƙarfin myeloma mai yawa

    Kudin CR na wata ɗaya

    Kudin PR na wata ɗaya

    Kudin wata ɗaya KO

    CRS≥3

    CRES≥3

    72.41%(21/29)

    27.59%(8/29)

    100% (29/29)

    Kashi 6.9%(2/29)

    0
    BAYANIN CIWON JINI NA CAR-T (2)ch

    Amfaninmu

    ● Jiyya ta Musamman: Kowace maganin CAR-T an keɓance ta ne ga majiyyaci, wanda ke tabbatar da sakamako mai kyau da inganci na magani.

    ● Zaɓuɓɓukan Niyya Mabanbanta: Tare da nau'ikan antigens iri-iri, ciki har da CD7, CD19, CD20, CD22, da BCMA, samfuranmu na CAR-T suna ba da damar yin amfani da su ba tare da wata matsala ba wajen magance cututtuka daban-daban na jini da cututtukan da ke shafar garkuwar jiki.

    ● Nasarar da aka Tabbatar a Asibiti: Magungunan mu na CAR-T sun nuna tasiri mai ban mamaki a cikin shari'o'i da yawa na asibiti, tare da kyawawan ƙimar sassauci da bayanan aminci, suna ƙarfafa matsayinmu a matsayin jagora a cikin maganin rigakafi.

    ● Ingantaccen Inganci Mai Girma: Muna bayar da fa'ida mai kyau tare da ingantattun jiyya a farashi mai sauƙin samu idan aka kwatanta da sauran samfuran CAR-T da ke kasuwa.

    ● Fasaha Mai Kyau: Ta hanyar amfani da sabbin ci gaba a fannin injiniyan kwayoyin halitta, hanyoyinmu na CAR-T sun ƙunshi makomar maganin cutar kansa da cututtukan da ke shafar garkuwar jiki.

    ● Tallafin Asibiti na Ƙwararru: Ƙungiyar likitocinmu masu ƙwarewa da masu bincike suna ba da cikakken kulawa tun daga lokacin da aka fara ba da shawara har zuwa lokacin da aka fara ba da magani da kuma bin diddiginsa.

    Yanzu an san ƙwayoyin CAR-T sosai saboda ingancinsu ga marasa lafiya waɗanda ba su amsa maganin gargajiya kamar chemotherapy ko dashen ƙashi ba. Ƙungiyar likitocin duniya ta amince da babban ƙarfin maganin CAR-T wajen canza sakamakon marasa lafiya.

    Karatu da kuma nazarin da suka shafi maganin CAR-T

    1. Maganin CAR-T don Lupus Erythematosus na Tsari: Inganci Mai Kyau a Shari'ar Yara
    Wani babban lamari a Asibitin Jami'ar Erlangen ya nuna ingancin maganin ƙwayoyin CAR-T wajen magance wata yarinya 'yar shekara 15 da ke fama da cutar lupus erythematosus (SLE). Bayan jerin magungunan da suka gaza, Uresa ta sami wannan sabuwar hanyar magani a watan Yunin 2023. Bayan makonni uku bayan magani, alamomin cutar sun inganta sosai, wanda ya haifar da cikakken murmurewa da dawo da aikin koda. Wannan nasarar ta zama farkon amfani da maganin CAR-T don cututtukan da ke shafar garkuwar jiki na yara, yana nuna yuwuwar samun gafara na dogon lokaci da kuma canza sakamakon marasa lafiya. Ana ci gaba da bincike don bincika aikace-aikacensa a cikin irin wannan yanayi.

    2. Maganin CAR-T don Myeloma da yawa: An Samu Gafara Mai Muhimmanci
    Bjørn Simensen, wani majiyyaci mai shekaru 67 daga ƙasar Norway, ya fuskanci gagarumin sauyi a yaƙin da yake yi da cutar myeloma mai yawa (IgG lambda, ISS-II) bayan ya sami maganin ƙwayoyin CAR-T. Da farko an gano shi a shekarar 2017, an yi masa wasu magungunan chemotherapy, amma ya sake komawa a shekarar 2021. Bayan jiyya marasa inganci, an tura shi zuwa Asibitin Lu Daopei a watan Fabrairun 2022, inda aka zaɓe shi don maganin CAR-T. Bayan an yi masa magani kafin a fara ba shi magani, an saka masa ƙwayoyin CAR-T. A ranar 28 ga wata, gwaje-gwajen da aka yi masa sun nuna babu ƙwayoyin plasma marasa kyau a cikin ƙashinsa, wanda hakan ya nuna babban nasara a maganinsa.

    3. CD7 Maganin CAR-T don T-ALL da LBL da suka sake dawowa: Inganci da Sakamako Mai Alfarma
    Binciken da aka yi kwanan nan ya nuna ingancin maganin CD7 chimeric antigen receptor T-cell (CAR-T) tare da dashen ƙwayoyin halitta na allogeneic hematopoietic na biyu (HSCT) ga marasa lafiya da suka sake kamuwa da cutar sankarar jini ta T-cell mai tsanani (T-ALL) da kuma cutar sankarar lymphoblastic (LBL). An gudanar da binciken a Asibitin Hebei Yanda Lu Daopei, wanda ya ƙunshi marasa lafiya 16 waɗanda suka sami mafi ƙarancin sassaucin raunin da ya rage (MRD) bayan magani. Tare da kashi 75% na cikakken sassaucin raunin da ya faru a waje da kuma kashi 58.5% na rayuwa gaba ɗaya da kuma kashi 51.4% na rayuwa gaba ɗaya ba tare da cutar sankarar jini ba, bi da bi, wannan sabuwar hanyar tana ba da sabon bege na tsawon lokaci na gafara a cikin waɗannan cututtukan daji masu tsanani.

    4. Maganin CAR-T don Cutar Leukemia Mai Tsanani ta B-Cell: Ingancin da Ba a Taba Ganinsa Ba
    Wani bincike da aka yi kwanan nan ya nuna ingancin maganin chimeric antigen receptor-T cell (CAR-T) wajen magance cutar sankarar jini ta B-cell mai saurin kamuwa da cutar sankarar jini ta B-cell (B-ALL). Binciken da aka gudanar tare da hadin gwiwar BIOOCUS da Asibitin Lu Daopei, ya nuna cewa adadi mai yawa na marasa lafiya sun sami cikakkiyar sassauci, inda suka sanya maganin CAR-T a matsayin babban zaɓi na magani ga wannan cutar sankarar jini mai tsanani. Sakamakon da aka samu mai kyau ya nuna yuwuwar sauyi na maganin CAR-T a fannin cutar kansa, yana ba da bege ga marasa lafiya da iyalai da ke fuskantar B-ALL. Yayin da bincike ke ci gaba, an shirya maganin CAR-T zai taka muhimmiyar rawa a nan gaba na maganin cutar kansa.

    Tsarin Jiyya na CAR-T

    1. Tarin T-Cell:
    Da farko, likitoci suna tattara ƙwayoyin T daga jinin majiyyaci ta amfani da wata hanya da ake kira leukapheresis. Wannan tsari yawanci yana ɗaukar kimanin awanni 4, inda mai raba jini zai ware ƙwayoyin farin jini da ake buƙata sannan ya mayar da sauran sassan jikin majiyyaci.
    2. Gyara da Faɗaɗa Halitta:
    Ana aika ƙwayoyin T da aka tattara zuwa dakin gwaje-gwaje don gyaran kwayoyin halitta. A wannan matakin, an ƙera ƙwayoyin T don kai hari da kuma lalata ƙwayoyin cutar kansa. Wannan tsari yana ɗaukar kimanin makonni 2-3. A wannan lokacin, ana kunna ƙwayoyin T kuma ana faɗaɗa su a cikin dakin gwaje-gwaje don tabbatar da ingancinsu akan cutar kansa.
    3. Jikowar Kwayoyin Halitta:
    Bayan an shirya ƙwayoyin T da aka ƙera, ana sake shigar da su cikin jikin majiyyaci ta hanyar jiko ta hanyar jijiya. Wannan matakin yana bawa ƙwayoyin garkuwar jiki da aka gyara damar gane da kuma kawar da ƙwayoyin cutar kansa yadda ya kamata.
    Marasa lafiya na iya fuskantar illa yayin magani, wanda ya fi yawa shine cutar sakin cytokine (CRS), wanda martanin garkuwar jiki ke haifarwa yayin lalata ƙwayoyin cutar kansa. Duk da cewa CRS na iya zama mai tsanani, ci gaban da aka samu a fannin kula da lafiya ya rage haɗarin da ke tattare da shi sosai.
    Duk tsawon lokacin magani, daga tarin ƙwayoyin halitta zuwa jiko, yawanci yana ɗaukar makonni 4-6, kodayake ainihin tsawon lokacin ya dogara da takamaiman yanayin majiyyaci.

    Cikakken Tallafi ga Marasa Lafiya na Ƙasashen Duniya da ke Tafiya zuwa BIOOCUS don Maganin CAR-T

    A BIOOCUS, mun himmatu wajen samar da kulawa da tallafi na musamman ga marasa lafiya na ƙasashen waje waɗanda ke neman maganin CAR-T. Ayyukanmu masu cikakken tsari sun shafi kowane mataki na tafiya, tun daga shirye-shiryen kafin tafiya zuwa kulawar bayan magani.
    1. Shiri Kafin Tafiya
    Kafin a yi tafiya zuwa BIOOCUS, marasa lafiya za su yi cikakken bincike a cibiyar kula da lafiya ta yankinsu. Wannan ya haɗa da cikakken nazari kan tarihin lafiya, gwaje-gwajen jiki, da gwaje-gwaje masu dacewa kamar aikin jini, nazarin hotuna, da gwaje-gwaje na musamman ga nau'in ciwon daji da ake yi wa magani (kamar cutar sankarar bargo, lymphoma, ko wasu cututtukan daji na jini). Muna tabbatar da cewa duk bayanan likita, gami da magunguna na baya, sakamakon gwaji, da kuma tabbatar da ganewar asali, an aika su zuwa ga ƙungiyarmu don dubawa da shiri.
    2. Tafiya da Asibiti
    Muna taimakawa da dukkan fannoni na tafiye-tafiye, gami da shirya masauki da kuma yin booking a cikin asibiti a Cibiyar Kiwon Lafiya ta Duniya ta BIOOCUS. Da isowarsu, ana shiryar da marasa lafiya ta hanyar tsarin shiga asibiti, wanda ke tabbatar da cewa an samu sauƙin sauyawa zuwa yanayin magani.
    3. Tsarin Magani
    Bayan an kwantar da marasa lafiya, za a yi musu gwaje-gwaje na farko, ciki har da tantancewa don tabbatar da cancantar yin maganin CAR-T. Wannan zai ƙunshi sake duba yanayin cutar kansar majiyyaci da lafiyarsa gaba ɗaya, da kuma tattara jini don cire ƙwayoyin T. Sannan ana aika ƙwayoyin T da aka tattara zuwa dakin gwaje-gwajenmu wanda GMP ta amince da shi don gyara kwayoyin halitta. Wannan tsari na iya ɗaukar kimanin makonni 2-3.
    4. Jiko na Kwayoyin Halitta da Kulawa Bayan Jiyya
    Da zarar ƙwayoyin CAR-T da aka gyara sun shirya, marasa lafiya za su koma asibitinmu don yin aikin jiko. Wannan magani ne na sau ɗaya inda ake ba da ƙwayoyin T da aka ƙera ta hanyar jijiya. Bayan jiko, marasa lafiya za su kasance a ƙarƙashin kulawa ta kusa na tsawon kwanaki da yawa don sa ido kan illolin da ke tattare da su, kamar su cutar sakin cytokine, wanda hakan na iya zama martani ga maganin. Ƙungiyar likitocinmu tana ba da tallafi da sa ido akai-akai a wannan mawuyacin lokaci.
    Bayan an sallame shi daga asibiti, BIOOCUS tana shirya ziyarar da za a yi masa akai-akai, gami da gwaje-gwajen dakin gwaje-gwaje da nazarin hotuna, don sa ido kan ingancin maganin da kuma bin diddigin murmurewar majiyyaci. Za a sa ido sosai kan marasa lafiya don ganin duk wani mummunan tasirin maganin a makare, kuma ƙungiyarmu za ta ci gaba da tuntuɓar su don ba da jagora da tallafi akai-akai.
    A BIOOCUS, muna ba da fifiko ga lafiya, aminci, da jin daɗin marasa lafiyarmu na ƙasashen waje. Manufarmu ita ce samar da cikakken kulawa da kuma tabbatar da samun ƙwarewa mai ƙarfi, ba tare da wata matsala ba a duk tsawon tafiyar maganin CAR-T.
    Domin ƙarin bayani game da ayyukanmu da kuma yadda za mu iya taimakawa wajen maganinku, da fatan za a tuntuɓe mu kai tsaye.

    bayanin2

    Submit An Free Inquiry

    Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

    AI Helps Write